This is consistent with our previous findings in cancer tissues, which showed that Zbed3 expression was associated with advanced TNM stages and lymph node metastasis of NSCLC.7 To determine whether Zbed3 increases β‐catenin through interaction with Axin, we prepared a Zbed3 mutant that lacked the Axin binding site. The gene discussed is AXIN1; the disease is cancer.